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Potential control of risperidone-related cognitive deficits by adjunctive
aripiprazole treatment
Abstract
We have read with great interest Uchida and colleagues’ paper in your journal (2009; 29: 571–576), which
reported that a high dosage of risperidone had a negative impact on cognition in older patients with
schizophrenia. This finding is consistent with that of a previous study of a younger patient group showing
that schizophrenia patients under high antipsychotic dosage have poor cognitive function performance....
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Editors,
We have read with great interest Uchida and colleagues’ paper in your journal (2009;
29: 571–576), which reported that a high dosage of risperidone had a negative impact
on cognition in older patients with schizophrenia1. This finding is consistent with that
of a previous study of a younger patient group showing that schizophrenia patients
under high antipsychotic dosage have poor cognitive function performance2. One key
issue is how to control risperidone related attention deficit. Uchida and colleagues
suggested minimizing the adverse effects of risperidone on cognitive function by
identifying/using the lowest effective dose of antipsychotics in schizophrenia patients1.
Although very valuable, a low dosage of risperidone may also cause adverse effects
on cognitive function3, which could be particularly problematic in aged patients due
to age-related pharmacodynamic and pharmacokinetic changes4. It is very important
that Uchida and colleagues identified that attention deficits induced by risperidone
negatively correlated with dopamine D2 receptor blockade1. We propose that an
adjunctive aripiprazole administration with rispirdone could be an effective method to
control risperidone related attention deficits (and other cognitive deficits) through
improving D2 receptor activity.

Aripiprazole is a newly introduced antipsychotic drug that has a favourable safety and
tolerability profile5, particularly in the elderly patients4. Aripiprazole was developed
as a potent D2 partial-agonist, 5-HT1A partial-agonist, and also 5-HT2A antagonist4,
however, recent studies have suggested that aripiprazole is not a simple

partial-agonist, but a functionally selective drug that can act as a D2 agonist or D2
antagonist depending on different brain regions6,7. It is possible that aripiprazole could
be used to control risperidone related attention deficits (caused by dopamine D2
receptor blockage) through its D2 agonistic effect. In fact, aripiprazole can
preferentially increase dopamine release in the medial prefrontal cortex and
hippocampus8 and dopamine synthesis in the nucleus accumbens6. A recent study has
shown that typical antipsychotic treatment resulted in hypoactivation in the dorsal
anterior cingulated cortex, which could be improved after switching to aripiprazole
and is correlated with improved performance of working memory9. Findling et al.10
examined the effectiveness and cognitive effects of aripiprazole in children with a
primary diagnosis of attention-deficit/hyperactivity disorder (ADHD), and showed
that aripiprazole led to clinical benefit in reducing ADHD symptoms and improving
cognition functioning. Moreover, adjunctive aripiprazole treatment has been trialled
in risperidone related hyperprolactinemia11,12 and olanzapine/clozapine-induced
obesity13,14. These studies showed that adjunctive treatment using aripiprazole with
other antipsychotics (such as risperidone and olanzapine) was generally safe and well
tolerated, and is effective even without reducing the original doses of other
antipsychtotics4,11,13,14. Therefore, co-administration of aripiprazole and risperidone
will result in multiple pharmacological actions and improve the adverse effects
beyond the attention deficits (such as weight gain15). Of course, further animal studies
and clinical trials are necessary for testing adjunctive aripiprazole/risperidone

treatment, especially in elderly patients that are at increased risk from drug–drug
interactions.
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